// COMPANY
Lycia Therapeutics
SECTOR BIOTECHMENTIONS 5LAST SEEN OCTOBER 27, 2026
// OVERVIEW
SF-based biotech targeting extracellular proteins, Nasdaq: LYCA
Discussed in
// RECENT MENTIONS
// SIGNALS
5 SIGNALS
01
funding·StrictlyVC·OCTOBER 27, 2026
“Lycia Therapeutics... raised $317.5 million in an upsized Nasdaq IPO, with shares closing their first day up nearly 67% at $30.”
Source→02
funding·PitchBook News·OCTOBER 26, 2026
“raised $317.5 million in its IPO.”
03
funding·Axios Pro Rata·OCTOBER 23, 2026
“It priced 17.6m shares at $18, versus plans to offer 14.7m at $16-$18. The Phase 1 company will list on Nasdaq (LYCA).”
04
AI-extracted from podcast / newsletter / paper summaries. May contain errors.